MiraLAX

MiraLAX is a consumer-health brand centered on polyethylene glycol 3350, an osmotic laxative used to relieve occasional constipation. The product is supplied as a powder intended to be dissolved in a beverage and generally works by retaining water in the stool, making bowel movements easier to pass. Unlike stimulant laxatives, polyethylene glycol 3350 is not designed to stimulate intestinal contractions directly; its principal effect is to increase the water content of stool. The brand is primarily associated with the United States over-the-counter market. Its best-known product is MiraLAX Powder, commonly sold in bottles or other retail pack formats. The product has historically been positioned around effective, gradual relief rather than an immediate stimulant effect. Label directions typically emphasize that the powder should be mixed into a liquid and that the product is intended for short-term, occasional constipation rather than indefinite self-treatment without medical advice. Polyethylene glycol 3350 had an established medical and prescription-use history before MiraLAX became an over-the-counter consumer brand. In the United States, the Food and Drug Administration approved a prescription formulation of polyethylene glycol 3350 for constipation in the late 1990s. MiraLAX was subsequently introduced as an over-the-counter product after FDA authorization in the 2000s. This transition expanded access to the ingredient through pharmacies, supermarkets, and mass retailers and made MiraLAX one of the most recognizable polyethylene glycol laxative brands in the American market. The brand’s commercial identity is closely tied to the active ingredient rather than to a broad portfolio of differentiated formulations. It competes with other osmotic laxatives, stimulant laxatives, stool softeners, fiber products, and generic polyethylene glycol 3350. Its consumer proposition has generally emphasized that the powder dissolves in a drink and is designed to provide relief without the cramping or urgency that consumers may associate with some stimulant products. Actual effects and tolerability vary, and product labeling directs consumers to seek professional advice for warning symptoms, prolonged constipation, or use in children outside the labeled directions. MiraLAX has also appeared in public discussion concerning reports of adverse events in children using polyethylene glycol 3350 products, including questions about trace impurities and possible neuropsychiatric symptoms. The FDA investigated these concerns and funded research; publicly available regulatory information has not established that MiraLAX causes the alleged effects. These discussions are distinct from the product’s approved adult over-the-counter labeling and should not be treated as proof of a confirmed brand defect. Ownership and marketing have changed within the consumer-health industry. The brand was associated with Schering-Plough and later with Merck following their corporate combination, before becoming part of the consumer-health portfolio acquired by Bayer from Merck in 2014. MiraLAX remains an active Bayer consumer-health brand in the United States, although precise corporate operating details, retail sales, and geographic expansion are not publicly established in the supplied reference material.

MiraLAX is a branded formulation of polyethylene glycol 3350, a water-soluble polymer used medically as an osmotic laxative. The ingredient’s medical role predates the consumer brand. In the United States, polyethylene glycol 3350 was developed and approved for prescription treatment of occasional constipation before the product became widely available without a prescription. Its mechanism is based on retaining water in the stool rather than directly stimulating intestinal contractions. The MiraLAX brand emerged as the ingredient moved into the American over-the-counter market. FDA authorization for nonprescription use expanded consumer access and allowed the product to be sold through pharmacies, supermarkets, and other mass-market retailers. The brand became associated with a powder that consumers mix into a beverage, an approach that distinguishes it operationally from tablets, suppositories, and ready-to-use stimulant laxatives. Its principal market remains the United States, and its public identity is concentrated on occasional constipation relief rather than on a wide therapeutic portfolio. Corporate ownership followed the consolidation of the consumer-health industry. MiraLAX was associated with Schering-Plough and subsequently with Merck after the two pharmaceutical companies combined in 2009. In 2014, Bayer completed the acquisition of Merck’s consumer-care business. The transaction transferred a large group of established nonprescription brands to Bayer and placed MiraLAX within Bayer’s consumer-health operations. Bayer AG is publicly listed, but MiraLAX itself is a brand and does not have a separate listing or publicly reported standalone financial statements in the supplied material. The brand’s history also includes regulatory and scientific scrutiny concerning pediatric use. Although MiraLAX’s over-the-counter labeling is directed primarily toward adults and older adolescents, polyethylene glycol 3350 products have been used in pediatric medical practice. Reports of behavioral or neuropsychiatric symptoms in some children led to public concern and FDA-sponsored investigation into possible impurities and safety signals. The FDA reported that available information did not demonstrate that polyethylene glycol 3350 causes the alleged neuropsychiatric effects, while research and professional discussion continued. This episode is best understood as a safety-investigation and labeling context rather than a confirmed recall or proven product scandal. Today, MiraLAX remains an active consumer-health brand focused on polyethylene glycol 3350 powder for occasional constipation. Its competitive environment includes generic polyethylene glycol 3350, other osmotic laxatives, stimulant laxatives, bulk-forming fiber, and stool-softener products. The supplied sources do not establish a separate international operating structure, current brand revenue, a complete executive history, or a definitive founding date for the MiraLAX name.

• 2014

  Transfer to Bayer consumer health

  [3]Bayer completes acquisition of Merck’s consumer-care businessbayer.com

  Bayer completed its acquisition of Merck’s consumer-care business, adding MiraLAX to its consumer-health portfolio.

• 2009

  Merger of Schering-Plough and Merck

  [4]Merck and Schering-Plough complete mergermerck.com

  The combination of Schering-Plough and Merck changed the corporate ownership context for consumer-health brands associated with the businesses.

• 2006

  MiraLAX receives over-the-counter authorization

  [2]FDA study of polyethylene glycol 3350fda.gov

  MiraLAX was authorized for nonprescription use, making polyethylene glycol 3350 more accessible to American consumers.

• 1999

  Prescription approval of polyethylene glycol 3350

  [5]Prescription approval of polyethylene glycol 3350accessdata.fda.gov

  The FDA approved polyethylene glycol 3350 for prescription treatment of occasional constipation in the United States.

An established over-the-counter osmotic laxative positioned around gradual relief from occasional constipation, convenient dissolution in beverages, and a non-stimulant mechanism.

• Over-the-counter osmotic laxative · 2006

  MiraLAX Powder

  The core MiraLAX product is a powder containing polyethylene glycol 3350. It is mixed into a beverage and used for occasional constipation relief. Polyethylene glycol 3350 works by holding water in the stool, which can soften stool and facilitate bowel movements. The product is generally associated with gradual relief rather than the rapid effect of some stimulant laxatives. Packaging, flavor presentation, and pack size may vary by market and retailer; the supplied sources do not establish a complete historical catalog of all variants.

• 2014

  Bayer acquisition of Merck consumer careM&A

  Background

  Merck elected to divest its consumer-care business as part of a broader portfolio strategy, while Bayer sought to expand its consumer-health presence.

  Action taken

  Bayer completed the acquisition of Merck’s consumer-care business, including brands associated with the MiraLAX portfolio.

  Aftermath

  MiraLAX became part of Bayer Consumer Health. The transaction did not make MiraLAX a separately listed company or separately reported public issuer.

  Transaction value. (2014)

  Source

• 2006

  Move from prescription ingredient to over-the-counter brandProduct launch

  Background

  Polyethylene glycol 3350 had previously been available in prescription treatment for constipation. Over-the-counter authorization created an opportunity to present the ingredient directly to consumers through retail health channels.

  Action taken

  MiraLAX was introduced for nonprescription use in the United States, with directions centered on dissolving the powder in a beverage for occasional constipation.

  Aftermath

  The product became a recognizable consumer brand in the U.S. laxative category. The available sources do not provide standalone sales figures or market-share results.

  Source

• 2014

  Bayer acquires Merck’s consumer-care business[3]Bayer completes acquisition of Merck’s consumer-care businessbayer.com

  M&A

  Bayer completed its acquisition of Merck’s consumer-care business, bringing brands including MiraLAX into Bayer’s consumer-health portfolio.

• 2014

  FDA continues research into polyethylene glycol 3350 use in children[2]FDA study of polyethylene glycol 3350fda.gov

  Regulation · Other

  The FDA described research into possible trace amounts of ethylene glycol and diethylene glycol in pediatric exposure to polyethylene glycol 3350 products. The agency stated that it had not established a causal link between use of these products and neuropsychiatric events.

• 2006

  MiraLAX enters the U.S. over-the-counter market[2]FDA study of polyethylene glycol 3350fda.gov

  Product launch · Regulation

  The FDA approved MiraLAX for nonprescription use in adults and children aged 17 and older, expanding access to polyethylene glycol 3350 through ordinary retail channels.

• 1999

  Polyethylene glycol 3350 receives U.S. prescription approval[5]Prescription approval of polyethylene glycol 3350accessdata.fda.gov

  Product launch

  The FDA approved polyethylene glycol 3350 for prescription treatment of occasional constipation, establishing the regulatory foundation for later consumer-market use of the ingredient.

1. 1Polyethylene glycolen.wikipedia.org
2. 2FDA study of polyethylene glycol 3350fda.gov
3. 3Bayer completes acquisition of Merck’s consumer-care businessbayer.com
4. 4Merck and Schering-Plough complete mergermerck.com
5. 5Prescription approval of polyethylene glycol 3350accessdata.fda.gov